UPDATE 1-SciClone to cut 17 pct US jobs, take related charge
2009-10-28 07:19:00.0
UPDATE 1-SciClone to cut 17 pct US jobs, take related charge | Reuters
Track China's Leaders
UPDATE 1-SciClone to cut 17 pct US jobs, take related charge
Mon, Oct 26 2009
Mon, Oct 5 2009
Fri, Oct 2 2009
Wed  EDT
) said it would cut about 17 percent of its U.S.-based jobs, mostly in research and development, following its decision to drop the development of its cancer drug earlier this month.
On Oct. 2, the company said it discontinued the development of its experimental pancreatic cancer drug after a recommendation by a data safety monitoring committee. [ID:nBNG485749]
SciClone said it expects to record a charge of about $0.3 million, which includes severance and other expenses associated with the workforce reduction.
The restructuring is expected to be complete in the fourth quarter, the company said in a statement.
SciClone sells Zadaxin, a drug approved in China and other overseas markets, to treat hepatitis B infections and to boost the immune systems of other patients, including those with liver cancer.
Shares of the company closed at $2.52 Tuesday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Himani Sarkar)
